• On sale!
  • Save €3.40
search

CRC500 60 CAPSULES

  • ERBOZETA SpA
  • 945254694
Features:


Crc 500 tablets Erbozeta is a food supplement based on Curcuma Meriva with antioxidant and anti-inflammatory action.






info_outline View product sheet
Final Price €28.50
Regular Price €31.90
Save €3.40
Quantity
check_circle Available
Shipped within 24 h
  Convenient and safe payments

Even with a credit card

  Shipping in 24h all over the world

Fast and safe international shipping worldwide

  Fast returns

14 days to reconsider

  Pharmaceutical experience

Always at your service. Experts in international shipping

Antioxidants Others products at unbeatable price

ERBOZETA SpA

Discover all products

CRC500 60 CAPSULES

CRC500

Description
Food supplement based on Meriva-Curcuma Phospholipid. Turmeric is useful for its antioxidant action.
MERIVA is a registered trademark owned by Indena SpA Italy.

Ingredients
Meriva-Curcuma Phospholipid rhizome dry extract (Curcuma longa L., soy lecithin) titrated 18-22% Curcuminoids, food gelatin, anti-caking agent: silicon dioxide; dyes: E171, E172.
Without gluten. Naturally devoid of lactose.

Nutritional characteristics
Average contentsper daily dose
(2 capsules)
MERIVA Curcuma Phospholipid 1000 mg

How to use
We recommend taking 2 capsules a day, one in the morning and one in the evening, preferably on a full stomach. You can open the capsule and pour the contents into a liquid (milk, yogurt, fruit juice).

Warnings
Keep out of the reach of children under three years of age. Do not exceed recommended daily doses. Supplements are not intended as a substitute for a varied, balanced diet and a healthy lifestyle. In case of alterations in the liver function, biliary or gallstones of the biliary tract, the use of the product is not recommended. If you are taking any medications, you should seek medical advice.

storage
Store in a cool and dry place, away from direct heat sources.
Validity in unopened package: 36 months.

Format
Blister of 60 capsules
ERBOZETA SpA
945254694
chat Comments (0)